Basic Information

Gene symbol PDCD1 Synonyms CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description programmed cell death 1

GTO ID GTC0317
Trial ID NCT02793856
Disease Metastatic Non-Small Cell Lung Cancer
Altered gene PDCD1
Therapeutic/Target gene Target gene
TherapyGene editing
Treatment PD-1 Knockout T cells
PhasePhase1
Recruitment statusCompleted
TitleA Phase I Clinical Trial of PD-1 Knockout Engineered T Cells Treating Patients With Advanced Non-small Cell Lung Cancer
Year2016
CountryChina
Company sponsorSichuan University
Other ID(s)MHC-001

Clinical Result

Cohort1: dose level 1
Administration route infusion
Dosage 1E7 cells/kg, 2E7 cells/kg, 4E7 cells/kg in one cycle, a total of two cycles of treatment. Each cycle is divided into three administrations, with 20%, 30% and 50% respectively.
Donor type autologous
Pts 22
Age Adult, Older_Adult
Outcome The median progression-free survival was 7.7 weeks (95% confidence interval, 6.9 to 8.5 weeks) and median overall survival was 42.6 weeks (95% confidence interval, 10.3-74.9 weeks).
Adverse reactions All treatment-related adverse events were grade 1/2
References PMID: 32341578

Relationship Graph

Overview of Knowledge Graph